Cellular immune response in patients with chronic hepatitis B virus infection

Microbial Pathogenesis

Volumn 74, Issue 1, 2014, Pages 59-62

  Li, Xuefen ^a   Wang, Yiyin ^a   Chen, Yu ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Cellular immune response; Clinical implications; Hepatitis B

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; LAMIVUDINE;

ANTIVIRAL THERAPY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOREGULATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; VIRAL CLEARANCE; VIRUS IMMUNITY; IMMUNOLOGY;

HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, CELLULAR;

EID: 84928548453     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2014.07.010     Document Type: Review

References (49)

1. World Health Organization. Global alert and response (GAR). Hepatitis B. Available from:: URL: html Accessed on 23.9.13. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index1.
2. Murray J.M., Wieland S.F., Purcell R.H., Chisari F.V. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci U S A 2005, 102(49):17780-17785.
3. Das A., Maini M.K. Innate and adaptive immune responses in hepatitis B virus infection. Dig Dis 2010, 28(1):126-132.
4. Bertoletti A., Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgrad Med J 2013, 89(1051):294-304.
5. Shimizu Y. Tcell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection. World J Gastroenterol 2012, 18(20):2443-2451.
6. Bauer T., Sprinzl M., Protzer U. Immune control of hepatitis B virus. Dig Dis 2011, 29(4):423-433.
7. Rouse B.T., Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome?. Nat Rev Immunol 2010, 10(7):514-526.
8. Bertoletti A., Maini M.K., Ferrari C. The host-pathogen interaction during HBV infection: immunological controversies. Antivir Ther 2010, 15(Suppl.3):15-24.
9. Chang J.J., Lewin S.R. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007, 85(1):16-23.
10. Wieland S.F., Chisari F.V. Stealth and cunning: hepatitis B and hepatitis C viruses. JVirol 2005, 79(15):9369-9380.
11. Fisicaro P., Valdatta C., Boni C., Massari M., Mori C., Zerbini A., et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009, 58(7):974-982.
12. Sprengers D., van der Molen R.G., Kusters J.G., De Man R.A., Niesters H.G., Schalm S.W., et al. Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans. JHepatol 2006, 45(2):182-189.
13. Zhang Z., Zhang J.Y., Wang L.F., Wang F.S. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. JGastroenterol Hepatol 2012, 27(2):223-230.
14. Chisari F.V., Isogawa M., Wieland S.F. Pathogenesis of hepatitis B virus infection. Pathol Biol Paris 2010, 58(4):258-266.
15. Chen S.H., Wu H.L., Kao J.H., Hwang L.H. Persistent hepatitis B viral replication in a FVB/N mouse model: impact of host and viral factors. PLoS One 2012, 7(5). e36984. 10.1371/journal.pone.0036984.
16. Walton S.M., Torti N., Mandaric S., Oxenius A. T-cell help permits memory CD8+ T-cell inflation during cytomegalovirus latency. Eur J Immunol 2011, 41(8):2248-2259.
17. Li X., Kong H., Tian L., Zhu Q., Wang Y., Dong Y., et al. Changes of costimulatory molecule CD28 on circulating CD8(+) T cells correlate with disease pathogenesis of chronic hepatitis B. Biomed Res Int 2014, 2014:423181. 10.1155/2014/423181.
18. Cao J., Zhang L., Huang S., Chen P., Zou L., Chen H., et al. Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis B. Microb Pathog 2011, 51(4):262-267.
19. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., et al. Coregulation of CD8+T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009, 10(1):29-37.
20. Wang X.F., Lei Y., Chen M., Chen C.B., Ren H., Shi T.D. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication. JViral Hepat 2013, 20(Suppl.1):27-39.
21. Wherry E.J. Tcell exhaustion. Nat Immunol 2011, 12(6):492-499.
22. Evans A., Riva A., Cooksley H., Phillips S., Puranik S., Nathwani A., et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008, 48(3):759-769.
23. Wongjitrat C., Sukwit S., Chuenchitra T., Seangjaruk P., Rojanasang P., Romputtan P., et al. CTLA-4 and its ligands on the surface of T- and B-lymphocyte subsets in chronic hepatitis B virus infection. JMed Assoc Thai 2013, 96(Suppl.1):S54-S59.
24. Li F.J., Zhang Y., Jin G.X., Yao L., Wu D.Q. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunol Lett 2013, 150(1-2):116-122.
25. Raziorrouh B., Schraut W., Gerlach T., Nowack D., Grüner N.H., Ulsenheimer A., et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 2010, 52(6):1934-1947.
26. Dario A.A., Lauren W.C., Creg J.W. How regulatory T cells work. Nat Rev Immunol 2008, 8(7):523-532.
27. Francisco L.M., Salinas V.H., Brown K.E., Vanguri V.K., Freeman G.J., Kuchroo V.K., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. JExp Med 2009, 206(13):3015-3029.
28. Ma H., Zhang H.H., Wei L. Frequency of T-cell FoxP3+ Treg and CD4+/CD8+ PD-1 expression is related to HBeAg seroconversion in hepatitis B patients on pegylated interferon. Chin Med J Engl 2013, 126(2):267-273.
29. Xu D., Fu J., Jin L., Zhang H., Zhou C., Zou Z., et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. JImmunol 2006, 177(1):739-747.
30. Stoop J.N., van der Molen R.G., Baan C.C., van der Laan L.J., Kuipers E.J., Kusters J.G., et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41(4):771-778.
31. Sprengers D., Stoop J.N., Binda R.S., Kusters J.G., Haagmans B.L., Carotenuto P., et al. Induction of regulatory T-cells and interleukin-10-producing cells in non-responders to pegylated interferon-alpha therapy for chronic hepatitis B. Antivir Ther 2007, 12(7):1087-1096.
32. Stoop J.N., van der Molen R.G., Kuipers E.J., Kusters J.G., Janssen H.L. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 2007, 361(1):141-148.
33. Li X., Chen Y., Ma Z., Ye B., Wu W., Li L. Effect of regulatory T cells and adherent cells on the expansion of HBcAg-specific CD8+ T cells in patients with chronic hepatitis B virus infection. Cell Immunol 2010, 264(1):42-46.
34. Chen Y., Wei H., Gao B., Hu Z., Zheng S., Tian Z. Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. JViral Hepat 2005, 12(1):38-45.
35. Albarran B., Goncalves L., Salmen S., Borges L., Fields H., Soyano A., et al. Profiles of NK, NKT cell activation and cytokine production following vaccination against hepatitis B. APMIS 2005, 113(7-8):526-535.
36. Zhao P.W., Jia F.Y., Shan Y.X., Ji H.F., Feng J.Y., Niu J.Q., et al. NK cell downregulation and altered function in hbv patients treated with entecavir. Clin Exp Pharmacol Physiol 2013, 40(3):190-196.
37. Oliviero B., Varchetta S., Paudice E., Michelone G., Zaramella M., Mavilio D., et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009, 137(3):1151-1160.
38. Bonorino P., Ramzan M., Camous X., Dufeu-Duchesne T., Thélu M.A., Sturm N., et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. JHepatol 2009, 51(3):458-467.
39. Li Y., Wang J.J., Gao S., Liu Q., Bai J., Zhao X.Q., et al. Decreased peripheral natural killer cells activity in the immune activated stage of chronic hepatitis B. PLoS One 2014, 9(2). e86927.
40. Ma Y.J., He M., Han J.A., Yang L., Ji X.Y. Aclinical study of HBsAg-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B. Scand J Immunol 2013, 78(4):387-393.
41. Duan X.Z., Zhuang H., Wang M., Li H.W., Liu J.C., Wang F.S. Decreased numbers and impaired function of circulating dendritic cell subsets in patients with chronic hepatitis B infection (R2). JGastroenterol Hepatol 2005, 20(2):234-242.
42. van der Molen R.G., Sprengers D., Biesta P.J., Kusters J.G., Janssen H.L. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 2006, 44(4):907-914.
43. Alatrakchi N., Koziel M.J. Antiviral T-cell responses and therapy in chronic hepatitis B. JHepatol 2003, 39(4):631-634.
44. Boni C., Laccabue D., Lampertico P., Giuberti T., Viganò M., Schivazappa S., et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012, 143(4):963-973.
45. Bertoletti A., Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012, 61(12):1754-1764.
46. Piao R.L., Liu Y.Y., Tian D., Ma Z.H., Zhang M., Zhao C., et al. Adefovir dipivoxil modulates cytokine expression in Th1/Th2 cells in patients with chronic hepatitis B. Mol Med Rep 2012, 5(1):184-189.
47. Rigopoulou E.I., Suri D., Chokshi S., Mullerova I., Rice S., Tedder R.S., et al. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005, 42:1028-1036.
48. Boni C., Penna A., Bertoletti A., Lamonaca V., Rapti I., Missale G., et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. JHepatol 2003, 39(4):595-605.
49. Chen Y., Li X., Ye B., Yang X., Wu W., Chen B., et al. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antivir Res 2011, 91(1):23-31.